Hepatology
Experts in the development and management of all aspects of MASH/MASLD, and viral hepatitis clinical trials
The voice of MASH investigators
Global survey provides insights for trial operations
Metabolic dysfunction-associated steatohepatitis (MASH), a component of metabolic syndrome, is an area of very active clinical development. To help determine the impact of this competitive environment for available and qualified site resources, as well as eligible patients, ICON undertook a global survey of MASH clinical trial sites across 37 different countries.
Digital solutions to alleviate MASH clinical trial challenges
The performance of MASH clinical trials presents many challenges unique to the field. Watch the on-demand webinar to learn about:
- The ability for digital technologies MRI, MRE and whole slide imaging to address MASH clinical trial challenges
- The ability of MRI and MRE to provide timely, high quality non-invasive solutions to enrolment
- The ability of whole slide imaging to facilitate rapid complex workflows that assure consistent high quality assessments of primary efficacy endpoints by enabling expert histopathologists to interact remotely and in real time.
Blogs and media contributions
-
Blog: MASH: Liver health’s silent epidemic
Learn about recent developments in MASH research and treatment and how Symphony Health data addresses the challenges of liver health’s silent epidemic.
-
Media article: Clinical trials - Keeping pace with shifting drug development paradigms for multi-indication therapies
In this article, learn how sponsors can drive multi-indication success through strategic trial design, early cross-functional planning, and evidence-driven development.
-
Media article: Unlocking the potential of GLP-1 based therapies with RWE
A recent ICON survey found fewer than 15% of sponsors use RWE to inform their multi-indication development strategy for obesity-related drugs. Learn best practices for leveraging RWE for GLP-1 based therapies in our article.
-
Media article: Embracing proactive multi-indication development for metabolic therapies
In this article, ICON expert , Alan Baldridge discusses how multi-indication development strategies are gaining traction, driven by successful trials across diverse diseases and the expansion of type 2 diabetes drugs into obesity and cardiovascular indications.
-
Media article: Strategic Commercialisation of Multi-Indication Obesity Therapies: Balancing Early Access, Pricing, and Lifecycle Value
A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the evolving cardiometabolic drug pipeline.
-
Media article: Survey of obesity developers suggests multi-indication approaches are vital but demanding
Following the rapid label expansion of drugs such as semaglutide and tirzepatide in recent years, drug developers have broadly adopted multi-indication strategies for obesity and related comorbidities. An ICON survey of 155 developers focused on these therapeutic areas reflects this growing trend.
-
Media article: Yearly trends in coverage rates for GLP-1 RAs in weight loss
New research from Symphony Health, an ICON plc company, featured in The American Journal of Managed Care (AMJC), highlights ongoing challenges in patient access to GLP-1 therapies for weight loss.
-
Media article: Tackling the next frontier in metabolic trials: A Q&A with ICON experts
In this article, ICON experts explore strategies to help sponsors navigate the evolving obesity research landscape, highlighting the use of adaptive designs, master protocols, and other innovative approaches.
Hepatology solutions
Discover more about ICON's solutions in the development and management of all aspects of MASH/MASLD, and viral hepatitis clinical trials clinical trials experts.